Vancomycin Price — China Factory EXW 2026

Vancomycin price Spec: China national standards

China EXW, VAT excluded

Newest China EXW USD 27,980.72 / MT · VAT excluded -2777.5841 (-9.00%) as of 20210323

Newest Price 27,980.72

Price Date 20210323

Day's Change -2,777.58

Day's Range 27,980.72 - 25,203.13

Month's Change -18,531.31

Month's Range 27,980.72 - 9,449.41

Year's Change +23,788.11

Year's Range 27,980.72 - 4,192.61

Geopolitical trade tensions could disrupt API flows. If US buyers diversify away from Chinese suppliers, domestic producers may face oversupply and price cuts. Conversely, stricter...

Also known as HSDB 3262, UNII-6Q205EH1VU, Vancoled, Vancomicina [INN-Spanish]

Opinions

What are the key supply chain and pricing dynamics for vancomycin API and formulations?

Geopolitical trade tensions could disrupt API flows. If US buyers diversify away from Chinese suppliers, domestic producers may face oversupply and price cuts. Conversely, stricter environmental regulations in China could raise production costs. Track export license changes and environmental inspections as leading indicators for price volatility.

Vancomycin price context

What drives Vancomycin prices

What are the key supply chain and pricing dynamics for vancomycin API and formulations?: Geopolitical trade tensions could disrupt API flows. If US buyers diversify away from Chinese suppliers, domestic producers may face oversupply and price cuts. ...

How we assess Vancomycin price

China factory / mainstream market EXW quotes (VAT excluded where shown) - not a single global public index

Regional and specification detail so buyers can compare like-for-like grades

Landed cost figures from our calculator are planning estimates, not a customs ruling

Overview

Vancomycin (万古霉素, CAS 1404-90-6) is a glycopeptide antibiotic with the formula C66H75Cl2N9O24 and a molecular weight of 1449.25. It appears as a solid that decomposes above 274°C, and it is a narrow-spectrum agent primarily active against Gram-positive bacteria, notably methicillin-resistant Staphylococcus aureus (MRSA).

Pharmaceutical: considered a key treatment for severe MRSA and other resistant Gram-positive infections; classified as a special-use antimicrobial in China, requiring senior physician approval.
Clinical: used for infections where standard beta-lactams fail; resistance concerns include VISA, VRSA, and VRE strains.
Regulatory: restricted to tertiary hospitals and inpatient use; not permitted in outpatient or primary care settings.

China's production landscape includes multiple domestic manufacturers, with Zhejiang Medicine, Hisun, and North China Pharmaceutical among those active. The market has seen generic consistency evaluations and national volume-based procurement (VBP) inclusions. Domestic producers supply both raw material and finished injectable forms, with some export presence.

Key domestic producers:
Zhejiang Medicine – major producer of vancomycin hydrochloride and teicoplanin.
Livzon Pharmaceutical – third domestic firm to pass consistency evaluation.
Zhejiang Hisun Pharmaceutical – holds approval for vancomycin hydrochloride for injection.
North China Pharmaceutical – offers a full glycopeptide portfolio including vancomycin and norvancomycin.

Properties

Name

Vancomycin

HSDB 3262

UNII-6Q205EH1VU

Vancoled

Vancomicina [INN-Spanish]

CAS Number

1404-90-6

EINECS No.

215-772-6

HS Code

2941900000

Cookie Preferences

Essential Cookies

Analytics Cookies

ChemPriceHub